Global Patent Index - EP 2086573 A4

EP 2086573 A4 20110629 - CEREBROSPINAL FLUID PURIFICATION SYSTEM

Title (en)

CEREBROSPINAL FLUID PURIFICATION SYSTEM

Title (de)

SYSTEM ZUR REINIGUNG VON LIQUOR

Title (fr)

SYSTÈME DE PURIFICATION DE FLUIDE CÉRÉBROSPINAL

Publication

EP 2086573 A4 20110629 (EN)

Application

EP 07873762 A 20071009

Priority

  • US 2007080834 W 20071009
  • US 82874506 P 20061009

Abstract (en)

[origin: WO2008105959A2] The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF). The methods provide for efficiently removing target compounds from CSF. The systems provide for a multilumen flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents. The invention finds use as a diagnostic, therapeutic and drug delivery platform for a variety of diseases affecting the CNS by accessing the CSF space. Exemplified disease conditions treatable by the present CSF processing systems and methods include, but are not limited to: Cerebral Vasospasm, Guillain Barre Syndrome, Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Spinal Cord Injury, Traumatic Brain Injury, Stroke, Cancer affecting the brain or spinal cord, Prion disease, Encephalitis from various causes, Meningitis from various causes, diseases secondary to enzymatic or metabolic imbalances, Biological Warfare, etc. For the first time, the present invention offers patients a disease-modifying, disruptive technology treatment platform that addresses the known disease pathogenesis of a number of neurologic conditions to which there are presently limited and ineffective treatment options.

IPC 8 full level

A61K 39/00 (2006.01)

CPC (source: EP US)

A61M 25/0026 (2013.01 - US); A61M 27/006 (2013.01 - EP US); A61M 1/3679 (2013.01 - EP US); A61M 2025/0007 (2013.01 - US); A61M 2027/004 (2013.01 - US); A61M 2202/0021 (2013.01 - US); A61M 2202/0464 (2013.01 - EP US); A61M 2202/203 (2013.01 - US); A61M 2202/206 (2013.01 - US); A61M 2206/16 (2013.01 - US); A61M 2210/0693 (2013.01 - US); A61M 2210/1003 (2013.01 - US)

Citation (search report)

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2008105959 A2 20080904; WO 2008105959 A3 20081224; EP 2086573 A2 20090812; EP 2086573 A4 20110629; EP 2086573 B1 20201125; EP 3827841 A1 20210602; EP 3827841 B1 20240403; ES 2845146 T3 20210726; JP 2010505556 A 20100225; JP 2014237048 A 20141218; JP 2016172087 A 20160929; JP 2016172088 A 20160929; JP 2018161560 A 20181018; JP 2019088849 A 20190613; JP 2021104377 A 20210726; JP 2021191531 A 20211216; JP 2022186892 A 20221215; JP 6244408 B2 20171206; JP 6492034 B2 20190327; JP 7127196 B2 20220829; JP 7461319 B2 20240403; US 10398884 B2 20190903; US 11065425 B2 20210720; US 2010305492 A1 20101202; US 2014066830 A1 20140306; US 2017203084 A1 20170720; US 2020046954 A1 20200213; US 2021386981 A1 20211216; US 2021386982 A1 20211216; US 8435204 B2 20130507; US 9895518 B2 20180220

DOCDB simple family (application)

US 2007080834 W 20071009; EP 07873762 A 20071009; EP 20209307 A 20071009; ES 07873762 T 20071009; JP 2009531646 A 20071009; JP 2014177177 A 20140901; JP 2016131320 A 20160701; JP 2016131321 A 20160701; JP 2018142352 A 20180730; JP 2019012875 A 20190129; JP 2021063570 A 20210402; JP 2021153052 A 20210921; JP 2022170566 A 20221025; US 201313801215 A 20130313; US 201715410219 A 20170119; US 201916548554 A 20190822; US 202117354388 A 20210622; US 202117354429 A 20210622; US 44458107 A 20071009